219 related articles for article (PubMed ID: 31589411)
1. A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
Biochemistry; 2019 Oct; 58(41):4246-4259. PubMed ID: 31589411
[TBL] [Abstract][Full Text] [Related]
2. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
4. Covalent vs. Non-Covalent Inhibition: Tackling Drug Resistance in EGFR - A Thorough Dynamic Perspective.
Akher FB; Farrokhzadeh A; Soliman MES
Chem Biodivers; 2019 Mar; 16(3):e1800518. PubMed ID: 30548188
[TBL] [Abstract][Full Text] [Related]
5. Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer.
Park H; Jung HY; Kim K; Kim M; Hong S
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297461
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the Mechanism of Binding Selectivity of Chlorofluoroacetamide-Based Covalent Inhibitors toward L858R/T790M Resistance Mutation.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
J Chem Inf Model; 2022 Feb; 62(4):997-1013. PubMed ID: 35119858
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the Inhibitory Activity.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
J Phys Chem B; 2020 Jul; 124(28):5813-5824. PubMed ID: 32603111
[TBL] [Abstract][Full Text] [Related]
8. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
[TBL] [Abstract][Full Text] [Related]
9. Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant.
Park J; McDonald JJ; Petter RC; Houk KN
J Chem Theory Comput; 2016 Apr; 12(4):2066-78. PubMed ID: 27010480
[TBL] [Abstract][Full Text] [Related]
10. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
Wang A; Li X; Wu H; Zou F; Yan XE; Chen C; Hu C; Yu K; Wang W; Zhao P; Wu J; Qi Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Yun CH; Liu J; Liu Q
J Med Chem; 2017 Apr; 60(7):2944-2962. PubMed ID: 28282122
[TBL] [Abstract][Full Text] [Related]
11. Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
Planken S; Behenna DC; Nair SK; Johnson TO; Nagata A; Almaden C; Bailey S; Ballard TE; Bernier L; Cheng H; Cho-Schultz S; Dalvie D; Deal JG; Dinh DM; Edwards MP; Ferre RA; Gajiwala KS; Hemkens M; Kania RS; Kath JC; Matthews J; Murray BW; Niessen S; Orr ST; Pairish M; Sach NW; Shen H; Shi M; Solowiej J; Tran K; Tseng E; Vicini P; Wang Y; Weinrich SL; Zhou R; Zientek M; Liu L; Luo Y; Xin S; Zhang C; Lafontaine J
J Med Chem; 2017 Apr; 60(7):3002-3019. PubMed ID: 28287730
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
Ding X; Liu X; Song X; Yao J
Mol Inform; 2016 Oct; 35(10):529-537. PubMed ID: 27643705
[TBL] [Abstract][Full Text] [Related]
13. Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor.
Yang Z; Yang H; Ai Y; Zhang L; Li Z; Wan S; Xu X; Zhang H; Wu S; Zhang J; Zhang T
Eur J Pharm Sci; 2020 Sep; 152():105463. PubMed ID: 32668314
[TBL] [Abstract][Full Text] [Related]
14. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Wang DD; Ma L; Wong MP; Lee VH; Yan H
PLoS One; 2015; 10(5):e0128360. PubMed ID: 25993617
[TBL] [Abstract][Full Text] [Related]
15. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
16. Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.
Hao Y; Lyu J; Qu R; Sun D; Zhao Z; Chen Z; Ding J; Xie H; Xu Y; Li H
Sci Rep; 2017 Jun; 7(1):3830. PubMed ID: 28630494
[TBL] [Abstract][Full Text] [Related]
17. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
18. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
[TBL] [Abstract][Full Text] [Related]
19. Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors.
Doss GP; Rajith B; Chakraborty C; NagaSundaram N; Ali SK; Zhu H
Sci Rep; 2014 Aug; 4():5868. PubMed ID: 25091415
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Cheng H; Nair SK; Murray BW; Almaden C; Bailey S; Baxi S; Behenna D; Cho-Schultz S; Dalvie D; Dinh DM; Edwards MP; Feng JL; Ferre RA; Gajiwala KS; Hemkens MD; Jackson-Fisher A; Jalaie M; Johnson TO; Kania RS; Kephart S; Lafontaine J; Lunney B; Liu KK; Liu Z; Matthews J; Nagata A; Niessen S; Ornelas MA; Orr ST; Pairish M; Planken S; Ren S; Richter D; Ryan K; Sach N; Shen H; Smeal T; Solowiej J; Sutton S; Tran K; Tseng E; Vernier W; Walls M; Wang S; Weinrich SL; Xin S; Xu H; Yin MJ; Zientek M; Zhou R; Kath JC
J Med Chem; 2016 Mar; 59(5):2005-24. PubMed ID: 26756222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
